Goldman Sachs Maintains Top Rating on Pfizer (PFE), Catalysts Ahead and Possible Full Break-Up
Go back to Goldman Sachs Maintains Top Rating on Pfizer (PFE), Catalysts Ahead and Possible Full Break-Up| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 48.93 +0.63 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.30 | 52 Week High | $77.12 | |||
| Open | $48.21 | 52 Week Low | $49.03 | |||
| Day High | $49.05 | P/E | 31.77 | |||
| Day Low | $48.12 | EPS | $1.54 | |||
| Volume | 10,303,895 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 26.00 +0.61 (2.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.39 | 52 Week High | $37.39 | |||
| Open | $25.39 | 52 Week Low | $28.25 | |||
| Day High | $26.00 | P/E | 15.76 | |||
| Day Low | $25.35 | EPS | $1.65 | |||
| Volume | 38,355,006 | |||||
